Member Info for MaverickD

Lind will now be looking to buy at the market price as opposed to converting at 17p.

Look at the terms of the investment announced in June 2020:

At any time, during the maturity period, the Investors may convert their Securities (in whole or in part) to 13,086,619 ordinary shares in the Company, in aggregate, at a price of 17.96p ("Conversion Price") which is equivalent to 120% of the Volume Weighted Average Price ("VWAP") of the ordinary shares for 09 June 2020.

During the maturity period, the Company may require the investors to convert their securities to ordinary shares, if the VWAP on each of at least 20 consecutive trading days shall be equal to or have exceeded 35.92p (200% of the Conversion Price).

I’m hoping to see the latter and volume weighted average price above 35.92.

Let’s see who can read between the lines on this one.

Avion submitted a special protocol assessment (SPA) request to the US regulators with the aim of streamlining the approval process for the clinical trial.

Discussions with a number of potential commercial partners outside the US – so further commercial upside for the drug.

The Avion deal will see ImmuPharma receive up to US$70mln of milestone payments, with US$5mln due on regulatory approval of the product and a further US$65mln dependent on sales targets.

The UK group will also get royalties of up to 17% on sales, while there are financial incentives to expand Lupuzor’s use into other autoimmune diseases.

The future is bright and the potential is massive.

Well I was right about the rns, but not one I had thought of. This is actually a positive in my view as there will be less dilution of the shares and the board can pay from funds held.I think we will see this bump upwards at open - not much, but 12p easily possible. The real meat on the bone here is FDA related or an update on Ureka.

There is a reason 25% of the business was mopped up........unfair it went so cheap, but all will come out in time.

Ureka news may well be imminent.......bodes well with all the CV work big pharma are undertaking right now. Any kind of positive testing or autoimmune response will see this SP soar!

Will land and many here will think why did I not add......happy to do so at these levels. managed to get 48k - order filled.

Should see the mms drag this higher after mopping up a few earlier. A number of the sale trades were in fact buys - dealers using the spread

Loading back up......looking for another 3p+ finish. Ignoring the noise!

Markets overall have pulled this down......should see this have another crack upwards

Re-rate and bounce to fair value!

Yes and that 2m buy that just went through at 2.77 is showing as a sell. Appears that some big funds are filling, or perhaps short positions being covered. Should get a holdings RNS and also need to check the short tracker for an update.
Last Friday was a bummer for the LTHs hoping tomorrow could be a lot better.

You you see the MMs pull the bid to get sells and then fill the big orders - ploy is clear here. I was wondering why Tims pals got eager to mop up 25% of the company.......they all have been given the heads up. I think that it's linked to Ureka or another one of their peptide research projects, because FDA news is pending. Someone knows something.....corrupt yes, but true.

Some investors only think about Lupazor - which is a big part yes, but not the only part of the business!

Little shake as the update could land at anytime. I would expect this to be back over 13p today and on release of the FDA trial approval we should easily be double where we are now

Little gap has been filled now the move up continues. Think there is another gap around the 3.3-3.5 mark. Then a bigger one at 3.8-4p.

Should see the momentum swinging in our favour now. Certainly feel a move up through 3p today. A number of chunky 500k buys yesterday and it appears a big buy filled at just above 2.815 last night, which explains why the Dealers held it back. Today should see a further gain - very positive trend developing

3p finish would be nice

few more 500k and a 1.5m too.....should see this go now

Being worked through at 2.8p

2.8p buys filled - next leg up. Long way to go to get to par value

Cash value 5.5-6p - shows how undervalued we are!